|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients with endometriosis (n = 150) and fertile controls (n = 199) were genotyped for polymorphisms in oestrogen receptor genes ESR1 (rs2234693 - T/C single nucleotide polymorphism (SNP), dinucleotide (TA)(n) repeat) and ESR2 (dinucleotide (CA)(n) repeat), progesterone receptor gene PGR (rs10895068 - G/A SNP, 306-bp Alu-insertion), 17β-hydroxysteroid dehydrogenase type 1 gene HSD17B1 (rs605059 - A/G SNP), and aromatase gene CYP19A1 (rs10046 - C/T SNP, (TTTA)(n) tetranucleotide repeat, 3-bp TCT insertion/deletion polymorphism).
|
20586553 |
2011 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Progesterone receptor +331G/A polymorphism in endometriosis and deep-infiltrating endometriosis.
|
18281038 |
2008 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a case-control study, we examined the PROGINS polymorphism of the progesterone receptor gene in 131 Italian women affected by endometriosis diagnosed according to published criteria for the definition of the definite disease.
|
15272913 |
2004 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The present study demonstrated that epigenetic changes occur in both promoter regions of the PGR gene in intestinal endometriosis.
|
24481237 |
2014 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the +331G/A progesterone receptor promoter polymorphism may modify the molecular epidemiologic pathway that encompasses both the development of endometriosis and its subsequent transformation into endometrioid/clear cell ovarian cancer.
|
15598772 |
2004 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genotypes P1P1, P1P2 and P2P2 (P2 representing the PROGINS polymorphism) of the progesterone receptor gene presented frequencies of 93.9%, 5.4% and 0.7%, respectively, in the women with endometriosis-associated infertility (p=0.2101, OR=0.51, 95% CI=0.24-1.09); 94.4%, 4.2% and 1.4%, respectively, in the patients with minimal/mild endometriosis (p=0.2725, OR=0.53, 95% CI=0.20-1.43); 93.5%, 6.5% and 0%, respectively, among the patients with moderate/severe endometriosis (p=0.3679, OR=0.49, 95% CI=0.18-1.31); 86.0%, 14.0% and 0%, respectively, in idiopathic infertile women (p=0.8146, OR=1.10, 95% CI=0.46-2.63); and 88.3%, 10.6% and 1.1%, respectively, in the control group.
|
21243274 |
2010 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We conclude that there is a significant correlation between PROGINS polymorphism and endometriosis.
|
21751163 |
2011 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort.
|
20719308 |
2011 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of the PR polymorphisms were determined in women with deep infiltrating endometriosis (n = 72), women with adenomyosis in the uterine wall (n = 40), gynaecological patients without symptomatic endometriosis (n = 102) and healthy females (n = 93).
|
16920727 |
2007 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Eutopic endometria were collected from three sources: women with endometriosis who had a single PROGINS allele (from the progesterone receptor gene); women with endometriosis who had the wild-type progesterone receptor allele; and women without endometriosis who had the wild-type allele.
|
19497994 |
2009 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The <i>PGR-A</i> gene showed 0% of DNA methylation (unmethylated) in both control and endometriosis groups.
|
30782101 |
2019 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association between the 306-base pair insertion polymorphism in intron G of the progesterone receptor (PROGINS) and endometriosis.
|
11821088 |
2002 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Endometriosis is often treated with progestins, which act as progesterone receptor agonists, although their exact mechanisms of action are not completely understood.
|
23183084 |
2013 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Genetic polymorphisms of cytochrome P450cl7alpha (CYP17) and progesterone receptor genes (PROGINS) in the assessment of endometriosis risk.
|
17484509 |
2007 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Progesterone receptor +331G/A polymorphism in endometriosis and deep-infiltrating endometriosis.
|
18281038 |
2008 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of the progesterone receptor gene polymorphism (PROGINS) with endometriosis: a meta-analysis.
|
24943061 |
2014 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We typed the 306 base pair Alu insertion (AluIns) polymorphism in intron G of PR in 101 individuals, estimated linkage disequilibrium (LD) between five single-nucleotide polymorphisms (SNPs) across the PR locus in 980 Australian triads (endometriosis case and two parents) and used transmission disequilibrium testing (TDT) for association with endometriosis.
|
16126772 |
2005 |
|
Endometriosis
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The frequencies of the PR polymorphisms were determined in women with deep infiltrating endometriosis (n = 72), women with adenomyosis in the uterine wall (n = 40), gynaecological patients without symptomatic endometriosis (n = 102) and healthy females (n = 93).
|
16920727 |
2007 |
|
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
While the exon 4-deleted, exon 6-deleted and exon 3,4-deleted PR variant mRNAs were observed in all samples analyzed, the exon 5,6-deleted, exon 4,5,6-deleted and/or exon 3,4,5,6-deleted PR variant mRNAs could not be detected in some cases, especially in poorly differentiated adenocarcinoma as compared with well-differentiated and moderately differentiated adenocarcinomas.
|
10644942 |
2000 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stratification analysis showed that rs13293512 CC genotype was associated with an increased risk of BC in patients with negative estrogen receptor (adjusted OR = 2.39; 95% CI: 1.32-4.30; <i>P=</i>0.004), patients with negative progesterone receptor (adjusted OR = 1.92; 95% CI: 1.11-3.33; <i>P=</i>0.02), patients with T1-2 stage cancer (adjusted OR = 1.77; 95% CI: 1.07-2.93; <i>P=</i>0.03), and patients with N1-3 stage cancer (adjusted OR = 1.89; 95% CI: 1.13-3.17; <i>P=</i>0.015).
|
31028134 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor.
|
20712647 |
2010 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, on performing stratified analysis between breast cancer risk and different clinicopathological characteristics, we observed strong associations for menopausal status, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, clinical stage, and histological grade.
|
24430361 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results provide further information regarding the association between the Alu insertion in the PGR gene and the incidence of breast cancer.
|
29370776 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to determine the frequency of p53 gene mutations in primary breast cancer, to correlate the presence of p53 mutations with established clinicopathologic parameters, including the estrogen receptor (ER) and progesterone receptor (PR) status, and to assess the prognostic significance of p53 mutations regarding patient survival.
|
8156519 |
1994 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of variance indicated a variable level of expression of both genes with regard to breast cancer grade (P = 0.00033 for glucocorticoid receptor and P = 0.023 for progesterone receptor).
|
12559052 |
2003 |